|
Sign In to gain access to subscriptions and/or personal tools.
|
Strategic Importance of Research Support through Pathology
Gary L. Cockerell
Global Toxicology, Pharmacia Corporation, Kalamazoo, Michigan, USA, gary.l.cockerell{at}pharmacia.com
James M. Mckim, JR
Global Toxicology, Pharmacia Corporation, Kalamazoo, Michigan, USA
Steven L. Vonderfecht
Global Toxicology, Pharmacia Corporation, Kalamazoo, Michigan, USA
The pace at which new drug candidates are being identified by Discovery Research demands that they be screened for preclinical attributes rapidly and efficiently. The early identification and elimination of compounds with toxic liabilities will produce safer drugs in a shorter time period, and with an increased rate of success. Most major pharmaceutical companies now recognize the strategic role of pathology support for research and have developed specific units to effect this outcome. The early interaction of these pathologists with drug discovery teams to identify compounds with toxic liabilities is critical. Approache s being used include high throughput in vitro screens to predict the relative toxicity of discovery compounds and to provide early indications of underlying mechanisms, target profiling to predict consequences of receptor-ligand interactions at other-than-indicated target sites, and acute in vivo studies to establish tolerability limits and target organs of toxicity. These approaches include the application of contemporary tools such as genomics, proteomics, metabonomics, and genetically engineered animal models. To maximize the benefit of discovery pathology, it is critical that pharmaceutical companies also actively participate in non-proprietary knowledge sharing and the education of pathologists and toxicologists to lead these efforts in the future.
Key Words: Benchmarking • education • investigative pathology and toxicology • in vitro toxicity screens • target organs of toxicity • target profiling • toxicology.
References
- CMR (2000). The Pharmaceutical R&D Compendium. Surrey, England: CMR International.
- Crouch SPM, Kozlowski R., Slater KJ, Fletcher J. (1993). The use of ATP-bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Meth 160: 81—88.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- DiMasi JA (2001). New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 69: 286—296.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Giannini E., Risso D., Ceppa P., Botta F., Chiarbonello B., Fasoli A., Malfatti F., Romagnoli P., Lantieri PB, Testa R. (2000). Utility of alpha-glutathione S-transferase assessment in chronic hepatitis C patients with near normal alanine aminotransferase levels. Clin Biochem 33: 297—301.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gonzalez RJ, Tarloff JB (2001). Evaluation of hepatic subcellular fractions for alamar blue and MTT reductase activity. Toxicol In Vitro 15: 257— 259.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gralinski MR (2000). The assessment of potential for QT interval prolongation with new pharmaceuticals: Impact on drug development. J Pharmacol Toxicol Meth 43: 91—99.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- McKim JM, Wilga PC, Petrella DK, Pregenzer JF, Patel RK, Cockerell GL (2001). A new approach to in vitro toxicity screening based on multi-endpoint analysis provides information of mechanism and predicts in vivo toxicity. Tox Sci Suppl 60: 306.
- Nicholson JK, Lindon JC, Holmes E. (1999). "Metabonomics:" Understanding the metabolic responses of living systems to pathophysiologica l stimuli via multivariate statistical analysis of biological NMR data. Xenobiotica 29: 1181—1189.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nuwaysir EM, Bittner M., Trent J., Barrett C., Afshari CA (1999). Microarrays and toxicology: The advent of toxicogneomics. Molec Carc 24: 153—159.[CrossRef]
- Rudmann DG, Durham SK (1999). Utilization of genetically altered animals in the pharmaceutical industry. Toxicol Pathol 27: 111—114.[Abstract/Free Full Text]
- Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphrey-Smith I., Hochstrasser DF, Williams KL (1996). Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13: 19—50.[Web of Science][Medline]
[Order article via Infotrieve]
- Wilson SM, Barsoum MJ, Wilson BW, Pappone PA (1999). Purine nucleotides modulate proliferation of brown fat preadipocytes. Cell Prolif 32: 131—140.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 30, No. 1,
4-7 (2002)
DOI: 10.1080/01926230252824644
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
